| Indicators | Browse All

Eledon Pharmaceuticals, Inc. (ELDN)

Healthcare | Biotechnology | Irvine, United States | NasdaqCM
3.20 USD -0.12 (-3.614%) ⇩ (Aug. 28, 2026, 4 p.m. EDT)
After hours: 3.21 +0.01 (0.312%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT)

Short-term:★★⯪☆☆Long-term:★☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | Aug. 22, 2026, 6:08 a.m. EDT

The long-term outlook is severely compromised by a decade-long structural decline; the stock has lost nearly 99% of its value over the last nine years, with seven of those years showing negative returns. Despite a recent surge in price and positive news regarding diabetes trials, the underlying business shows no signs of recovery, evidenced by negative earnings, negative free cash flow, and a return on equity of -110%. The balance sheet, while currently debt-light, is being eroded by significant cash burn. Short-term momentum is mixed; the stock recently rallied but is now trading below its 50-day moving average, and the statistical forecast model offers no directional guidance. Options activity confirms a bearish sentiment, with traders aggressively buying puts to hedge against further deterioration rather than betting on a near-term reversal. Without a proven path to profitability or a clear turnaround in revenue growth, the investment case remains fundamentally broken.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.055295
AutoARIMA0.056801
AutoETS0.056802
AutoTheta0.143153

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 40%
H-stat 1.38
Ljung-Box p 0.000
Jarque-Bera p 0.302
Excess Kurtosis -1.12
Attribute Value
Sector Healthcare
Debt to Equity Ratio 0.648
Market Cap 260,035,696
Forward P/E -4.16
Beta 0.96
Website https://eledon.com

As of Aug. 22, 2026, 6:08 a.m. EDT: Speculators are heavily positioned for downside protection, with massive open interest in out-of-the-money puts relative to calls. The put/call ratio is skewed significantly toward selling, while call volume is concentrated at strikes far above the current price, indicating a lack of immediate bullish conviction despite some speculative upside bets.


Info Dump

Attribute Value
52 Week Change 0.254902
Address1 19,800 MacArthur Boulevard
Address2 Suite 250
All Time High 4,860.0
All Time Low 1.07
Ask 4.13
Ask Size 2
Audit Risk 10
Average Analyst Rating 1.0 - Strong Buy
Average Daily Volume10 Day 882,010
Average Daily Volume3 Month 1,268,996
Average Volume 1,268,996
Average Volume10Days 882,010
Beta 0.956
Bid 2.38
Bid Size 2
Board Risk 7
Book Value 0.89
City Irvine
Compensation As Of Epoch Date 1,767,139,200
Compensation Risk 9
Country United States
Crypto Tradeable 0
Currency USD
Current Price 3.2
Current Ratio 7.896
Custom Price Alert Confidence HIGH
Date Short Interest 1,786,665,600
Day High 3.32
Day Low 3.17
Debt To Equity 0.648
Display Name Eledon Pharmaceuticals
Dividend Date 1,601,856,000
Earnings Timestamp End 1,794,600,000
Earnings Timestamp Start 1,794,600,000
Ebitda Margins 0.0
Enterprise Value 171,746,688
Eps Current Year -0.9325
Eps Forward -0.77
Eps Trailing Twelve Months -0.87
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 3.7002
Fifty Day Average Change -0.50020003
Fifty Day Average Change Percent -0.13518189
Fifty Two Week Change Percent 25.4902
Fifty Two Week High 4.6
Fifty Two Week High Change -1.3999999
Fifty Two Week High Change Percent -0.3043478
Fifty Two Week Low 1.35
Fifty Two Week Low Change 1.85
Fifty Two Week Low Change Percent 1.3703704
Fifty Two Week Range 1.35 - 4.6
Financial Currency USD
First Trade Date Milliseconds 1,410,960,600,000
Float Shares 74,596,112
Forward Eps -0.77
Forward P E -4.155844
Free Cashflow -45,104,500
Full Exchange Name NasdaqCM
Full Time Employees 33
Fullday Change -0.12
Fullday Change Percent -3.61445
Fullday Price 3.21
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,785,542,400
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.00329
Held Percent Institutions 0.62481
Implied Shares Outstanding 81,261,152
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,601,856,000
Last Split Factor 1:18
Long Business Summary Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Long Name Eledon Pharmaceuticals, Inc.
Market us_market
Market Cap 260,035,696
Market State CLOSED
Max Age 86,400
Message Board Id finmb_62494905
Most Recent Quarter 1,782,777,600
Net Income To Common -98,561,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 269,787,024
Number Of Analyst Opinions 5
Open 3.29
Operating Cashflow -73,857,000
Operating Margins 0.0
Overall Risk 9
Payout Ratio 0.0
Phone 949 238 8090
Post Market Change 0.00999999
Post Market Change Percent 0.3124997
Post Market Price 3.21
Post Market Time 1,787,959,806
Previous Close 3.32
Price Eps Current Year -3.4316354
Price Hint 4
Price To Book 3.5955057
Profit Margins 0.0
Quick Ratio 7.565
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.0
Region US
Regular Market Change -0.12
Regular Market Change Percent -3.61445
Regular Market Day High 3.32
Regular Market Day Low 3.17
Regular Market Day Range 3.17 - 3.32
Regular Market Open 3.29
Regular Market Previous Close 3.32
Regular Market Price 3.2
Regular Market Time 1,787,947,201
Regular Market Volume 1,014,524
Return On Assets -0.39023998
Return On Equity -1.10706
Sand P52 Week Change 0.20204377
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 7
Shares Outstanding 81,261,152
Shares Percent Shares Out 0.0774
Shares Short 6,289,078
Shares Short Previous Month Date 1,784,073,600
Shares Short Prior Month 5,522,678
Short Name Eledon Pharmaceuticals, Inc.
Short Percent Of Float 0.0774
Short Ratio 6.52
Source Interval 15
State CA
Symbol ELDN
Target High Price 12.0
Target Low Price 7.0
Target Mean Price 9.0
Target Median Price 8.0
Total Cash 88,756,000
Total Cash Per Share 1.092
Total Debt 467,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -0.87
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 2.898425
Two Hundred Day Average Change 0.30157495
Two Hundred Day Average Change Percent 0.104047865
Type Disp Equity
Volume 1,014,524
Website https://eledon.com
Zip 92,612